A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults
Open Access
- 10 June 2020
- Vol. 8 (2), 296
- https://doi.org/10.3390/vaccines8020296
Abstract
This study describes a double-blind randomized placebo-controlled phase I clinical trial in healthy adults of a new potential pandemic H7N9 live attenuated influenza vaccine (LAIV) based on the human influenza virus of Yangtze River Delta hemagglutinin lineage (ClinicalTrials.gov Identifier: NCT03739229). Two doses of H7N9 LAIV or placebo were administered intranasally to 30 and 10 subjects, respectively. The vaccine was well-tolerated and not associated with increased rates of adverse events or with any serious adverse events. Vaccine virus was detected in nasal swabs during the 6 days after vaccination or revaccination. A lower frequency of shedding was observed after the second vaccination. Twenty-five clinical viral isolates obtained after the first and second doses of vaccine retained the temperature-sensitive and cold-adapted phenotypic characteristics of LAIV. There was no confirmed transmission of the vaccine strain from vaccinees to placebo recipients. After the two H7N9 LAIV doses, an immune response was observed in 96.6% of subjects in at least one of the assays conducted.Funding Information
- Biomedical Advanced Research and Development Authority (IDSEP130015-01)
This publication has 55 references indexed in Scilit:
- Human infection with avian influenza A H7N9 virus: an assessment of clinical severityThe Lancet, 2013
- Use it or lose it: establishment and persistence of T cell memoryFrontiers in Immunology, 2012
- Infection of immunocompromised patients by avian H9N2 influenza A virusJournal of Infection, 2011
- The resurgence of swine-origin influenza A (H1N1)Cleveland Clinic Journal of Medicine, 2009
- Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I–II clinical trials)Influenza and Other Respiratory Viruses, 2008
- A Randomized, Double-Blind Study of the Safety, Transmissibility and Phenotypic and Genotypic Stability of Cold-Adapted Influenza Virus VaccineThe Pediatric Infectious Disease Journal, 2006
- Central Memory and Effector Memory T Cell Subsets: Function, Generation, and MaintenanceAnnual Review of Immunology, 2004
- Universal primer set for the full-length amplification of all influenza A virusesArchiv für die gesamte Virusforschung, 2001
- Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory IllnessScience, 1998
- Pilot Studies on Recombinant Cold-Adapted Live Type A and B Influenza Virus VaccinesThe Journal of Infectious Diseases, 1977